title: 5,10-Methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTRR), and methionine synthase reductase (MTR) gene polymorphisms and adult meningioma risk.
abstract: The causes of meningiomas are not well understood. Folate metabolism gene polymorphisms have been shown to be associated with various human cancers. It is still controversial and ambiguous between the functional polymorphisms of folate metabolism genes 5,10-methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTRR), and methionine synthase reductase (MTR) and risk of adult meningioma. A population-based case–control study involving 600 meningioma patients (World Health Organization [WHO] Grade I, 391 cases; WHO Grade II, 167 cases; WHO Grade III, 42 cases) and 600 controls was done for the MTHFR C677T and A1298C, MTRR A66G, and MTR A2756G variants in Chinese Han population. The folate metabolism gene polymorphisms were determined by using a polymerase chain reaction–restriction fragment length polymorphism assay. Meningioma cases had a significantly lower frequency of MTHFR 677 TT genotype [odds ratio (OR) = 0.49, 95 % confidence interval (CI) 0.33–0.74; P = 0.001] and T allele (OR = 0.80, 95 % CI 0.67–0.95; P = 0.01) than controls. A significant association between risk of meningioma and MTRR 66 GG (OR = 1.41, 95 % CI 1.02–1.96; P = 0.04) was also observed. When stratifying by the WHO grade of meningioma, no association was found. Our study suggested that MTHFR C677T and MTRR A66G variants may affect the risk of adult meningioma in Chinese Han population.
authors: Jun
authors: J
authors: Zhang
authors: Yan-Wen
authors: YW
authors: Zhou
authors: Hua-Ping
authors: HP
authors: Shi
authors: Yan-Zhong
authors: YZ
authors: Wang
authors: Gui-Ling
authors: GL
authors: Li
authors: Hai-Tao
authors: HT
authors: Yu
authors: Xin-You
authors: XY
authors: Xie
mesh_terms: D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / Q000235:genetics*; D000328:Adult; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D005260:Female; D005287:Ferredoxin-NADP Reductase / Q000235:genetics*; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D008579:Meningioma / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors
chemical_list: C111241:methionine synthase reductase; D005287:Ferredoxin-NADP Reductase; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; C585801:MTR protein, human
references: Breast Cancer Res Treat. 2010 Sep;123(2):499-506
references: 20135343
references: Mol Med Rep. 2011 Jan-Feb;4(1):175-9
references: 21461582
references: Mol Med Rep. 2012 Apr;5(4):1011-8
references: 22293950
references: Lancet Oncol. 2007 May;8(5):403-10
references: 17466897
references: Hum Mol Genet. 1996 Dec;5(12):1867-74
references: 8968737
references: Gene. 2013 Mar 10;516(2):291-3
references: 23276705
references: J Int Med Res. 2010 May-Jun;38(3):870-83
references: 20819423
references: Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
references: 23095881
references: Asian Pac J Cancer Prev. 2011;12(9):2275-8
references: 22296369
references: Psychiatr Genet. 2010 Aug;20(4):187-9
references: 20440228
references: Asian Pac J Cancer Prev. 2012;13(2):569-73
references: 22524826
references: J Neurosurg. 2008 May;108(5):999-1004
references: 18447718
references: Int J Cancer. 2011 Feb 1;128(3):644-52
references: 20473868
references: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1195-202
references: 18483342
references: Anticancer Res. 2006 May-Jun;26(3B):2445-9
references: 16821630
references: Br J Cancer. 2011 Mar 15;104(6):1049-54
references: 21364586
references: Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):865-71
references: 22138457
references: Biochemistry. 2002 Nov 12;41(45):13378-85
references: 12416982
references: Asian Pac J Cancer Prev. 2012;13(4):1203-8
references: 22799306
references: Genet Test Mol Biomarkers. 2009 Dec;13(6):817-20
references: 19810824
references: Nat Genet. 2011 Jul 31;43(9):825-7
references: 21804547
references: Atherosclerosis. 2001 Aug;157(2):451-6
references: 11472746
references: J Genet. 2010 Aug;89(2):263-7
references: 20861582
references: J Int Med Res. 2011;39(5):1728-35
references: 22117973
references: Int J Cancer. 1999 Oct 29;83(3):299-304
references: 10495419
references: Asian Pac J Cancer Prev. 2011;12(8):2019-23
references: 22292644
references: Asian Pac J Cancer Prev. 2011;12(9):2227-32
references: 22296361
references: Anticancer Res. 2011 Jun;31(6):2395-9
references: 21737671
references: Cancer Res. 2002 Aug 1;62(15):4519-24
references: 12154064
references: BMC Cancer. 2011 Oct 25;11:459
references: 22024018
references: Carcinogenesis. 2007 Feb;28(2):390-7
references: 16950800
references: Nat Genet. 1995 May;10(1):111-3
references: 7647779
references: Pharmacogenet Genomics. 2005 Aug;15(8):547-55
references: 16006998
references: Int J Mol Sci. 2012;13(4):4009-20
references: 22605962
references: Int J Biol Sci. 2012;8(6):819-30
references: 22719222
references: Mol Genet Metab. 1998 Jul;64(3):169-72
references: 9719624
references: Asian Pac J Cancer Prev. 2002;3(4):353-359
references: 12716294
references: Cancer Causes Control. 2011 Jan;22(1):63-72
references: 21052817
references: Nat Protoc. 2006;1(2):581-5
references: 17406285
references: Breast Cancer Res Treat. 2010 Sep;123(2):549-55
references: 20143151
references: Neuro Oncol. 2011 Mar;13(3):345-52
references: 21339193
references: Mol Med Rep. 2010 Sep-Oct;3(5):741-7
references: 21472308
references: Anal Biochem. 1987 Apr;162(1):156-9
references: 2440339